Yoshikazu Ohtsuka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoshikazu Ohtsuka has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Toshiaki Shimizu
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan
15 shared publications Toshiaki Shimizu
Department of Pediatrics and Adolescent Medicine Juntendo University Graduate School of Medicine Tokyo Japan
11 shared publicationsTohru Fujii
Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
10 shared publicationsYo Aoyagi
Department of Pediatrics Juntendo University Faculty of Medicine Tokyo Japan
9 shared publicationsTakahiro Kudo
Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
8 shared publications- Takahiro Kudo
Department of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan
8 shared publications
Latest Publications
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8)
Threshold heterogeneity and dose‐related clinical reaction profiles in infantile food protein‐induced enterocolitis syndrome
Background: Oral food challenge (OFC) protocols in food protein‐induced enterocolitis syndrome (FPIES) often select starting doses with consideration of prior reaction severity, implying that dose may influence reaction intensity; however, patient‐level evidence linking antigen dose to reaction profiles remains limited. Objective: To characterize threshold heterogeneity and compare clinical reaction profiles between diagnostic and reactive threshold OFCs within individual patients. Methods: In this prospective study, 54 infants with OFC‐confirmed FPIES (egg yolk, 36; cow's milk, 18) underwent threshold characterization at 0.001 g/kg (ultra‐low) and 0.01 g/kg (low); all had previously reacted at a diagnostic OFC (median 0.38 g/kg). For the 30 reacting at a threshold challenge, the primary endpoint was objective reaction intensity (vomiting, examination signs); treatment intensity and a composite burden category were supporting measures. Results: Of 54 patients, 12 (22%) reacted at 0.001 g/kg, 18 (33%) at 0.01 g/kg, and 24 (44%) tolerated both. Among the 30 threshold reactors, reactions were objectively milder than at the diagnostic OFC: median vomiting 2 (IQR 2–3) versus 4 (4–6) ( p < .001), pallor 27% versus 63% ( p = .019), decreased activity 43% versus 80% ( p = .007). No ICG‐defined severe features (hypotension/shock, severe lethargy) occurred at either OFC. Treatment intensity was also lower (intravenous fluid and prolonged observation each 27% versus 67%; both p < .001). Conclusion: Reactions at ultra‐low and low threshold doses were objectively milder than at diagnostic doses within patients, while clinically meaningful reactions still occurred. These findings support systematic threshold assessment beginning at 0.001 g/kg, independent of diagnostic OFC clinical burden. image
- 17 August 2026
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 37 (8)
Threshold heterogeneity and dose‐related clinical reaction profiles in infantile food protein‐induced enterocolitis syndrome
Background: Oral food challenge (OFC) protocols in food protein‐induced enterocolitis syndrome (FPIES) often select starting doses with consideration of prior reaction severity, implying that dose may influence reaction intensity; however, patient‐level evidence linking antigen dose to reaction profiles remains limited. Objective: To characterize threshold heterogeneity and compare clinical reaction profiles between diagnostic and reactive threshold OFCs within individual patients. Methods: In this prospective study, 54 infants with OFC‐confirmed FPIES (egg yolk, 36; cow's milk, 18) underwent threshold characterization at 0.001 g/kg (ultra‐low) and 0.01 g/kg (low); all had previously reacted at a diagnostic OFC (median 0.38 g/kg). For the 30 reacting at a threshold challenge, the primary endpoint was objective reaction intensity (vomiting, examination signs); treatment intensity and a composite burden category were supporting measures. Results: Of 54 patients, 12 (22%) reacted at 0.001 g/kg, 18 (33%) at 0.01 g/kg, and 24 (44%) tolerated both. Among the 30 threshold reactors, reactions were objectively milder than at the diagnostic OFC: median vomiting 2 (IQR 2–3) versus 4 (4–6) ( p < .001), pallor 27% versus 63% ( p = .019), decreased activity 43% versus 80% ( p = .007). No ICG‐defined severe features (hypotension/shock, severe lethargy) occurred at either OFC. Treatment intensity was also lower (intravenous fluid and prolonged observation each 27% versus 67%; both p < .001). Conclusion: Reactions at ultra‐low and low threshold doses were objectively milder than at diagnostic doses within patients, while clinically meaningful reactions still occurred. These findings support systematic threshold assessment beginning at 0.001 g/kg, independent of diagnostic OFC clinical burden. image
- Open Access
- 5 January 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (2)
Constitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice
IL-33-induced signals via membrane-bound ST2 (ST2L) are critical for allergies. However, the physiological role of endogenous soluble ST2 (sST2) remains elusive. Here, we generated sST2-deficient mice with intact ST2L using the CRISPR/Cas9 system. Skin fibroblasts constitutively released sST2 protein at extremely high levels compared to mast cells, which did not reflect the expression levels of sST2 mRNA. This discrepancy can be partly explained by the sST2 protein degradation mediated by mast cell proteases. Accordingly, sST2 deficiency did not affect IL-33- and/or IgE plus antigen-stimulated mast cell activation in vitro. We provided evidence that constitutively high levels of sST2 suppress food allergies in mice by inhibiting IL-33-dependent, both expansion of jejunum mast cells and enhancement of their degranulation. Analysis of bone marrow chimeric mice under steady-state conditions showed that circulating sST2 was derived almost equally from hematopoietic and nonhematopoietic cells. Increased circulating sST2 in food-allergic mice was possibly and partly derived from fibroblasts stimulated by locally released IL-4 and IL-13. In conclusion, endogenous sST2 contributes to the suppression of food allergies.
- 5 January 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (2)
Open AccessConstitutively high levels of endogenous soluble ST2 inhibit food allergic responses in mice
IL-33-induced signals via membrane-bound ST2 (ST2L) are critical for allergies. However, the physiological role of endogenous soluble ST2 (sST2) remains elusive. Here, we generated sST2-deficient mice with intact ST2L using the CRISPR/Cas9 system. Skin fibroblasts constitutively released sST2 protein at extremely high levels compared to mast cells, which did not reflect the expression levels of sST2 mRNA. This discrepancy can be partly explained by the sST2 protein degradation mediated by mast cell proteases. Accordingly, sST2 deficiency did not affect IL-33- and/or IgE plus antigen-stimulated mast cell activation in vitro. We provided evidence that constitutively high levels of sST2 suppress food allergies in mice by inhibiting IL-33-dependent, both expansion of jejunum mast cells and enhancement of their degranulation. Analysis of bone marrow chimeric mice under steady-state conditions showed that circulating sST2 was derived almost equally from hematopoietic and nonhematopoietic cells. Increased circulating sST2 in food-allergic mice was possibly and partly derived from fibroblasts stimulated by locally released IL-4 and IL-13. In conclusion, endogenous sST2 contributes to the suppression of food allergies.
- Open Access
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70508
Is Procedural Intravenous Anesthesia Safe for Children? An Analysis of Nationwide Accident Registries in Japan
Background: Although pediatric intravenous anesthesia is widely employed outside operating rooms, it poses risks for serious complications such as airway obstruction and apnea. In Japan, the actual numbers and trends of medical accidents associated with pediatric intravenous anesthesia remain unclear, and the safety of procedural intravenous anesthesia in children has not been sufficiently investigated. Methods: We extracted accident reports on pediatric intravenous anesthesia for medical procedures from a nationwide, anonymized Japanese accident registry database over 13 years. The reports were analyzed to describe the clinical characteristics of the reported severe adverse events. Results: A total of 79 accident reports related to intravenous anesthesia were registered, accounting for 0.017% of the total number of intravenous anesthesia procedures. Among these, 70 (88.6%) accident cases occurred in children aged 0–9 years and 9 (11.8%) in patients older than 10 years. Four cases resulted in death and eight in cardiopulmonary arrest, all involving serious underlying medical conditions and occurring during prolonged and highly invasive procedures. When categorized by age, six cases (75.0%) involved children aged 0–9 years and 2 (25.0%) involved patients older than 10 years. The most common underlying disease categories were cardiac disease ( n = 7) and the most frequent procedures were cardiac catheterization ( n = 5). The number of physicians exclusively assigned to anesthesia induction and monitoring using capnometers was not reported. Conclusions: This nationwide registry analysis characterizes severe pediatric intravenous anesthesia–related adverse events in Japan and highlights the importance of risk stratification and specialist involvement in high‐risk cases.
- 1 January 2026
- Published by Wiley in Pediatrics International
- Vol. 68 (1) , e70508
Open AccessIs Procedural Intravenous Anesthesia Safe for Children? An Analysis of Nationwide Accident Registries in Japan
Background: Although pediatric intravenous anesthesia is widely employed outside operating rooms, it poses risks for serious complications such as airway obstruction and apnea. In Japan, the actual numbers and trends of medical accidents associated with pediatric intravenous anesthesia remain unclear, and the safety of procedural intravenous anesthesia in children has not been sufficiently investigated. Methods: We extracted accident reports on pediatric intravenous anesthesia for medical procedures from a nationwide, anonymized Japanese accident registry database over 13 years. The reports were analyzed to describe the clinical characteristics of the reported severe adverse events. Results: A total of 79 accident reports related to intravenous anesthesia were registered, accounting for 0.017% of the total number of intravenous anesthesia procedures. Among these, 70 (88.6%) accident cases occurred in children aged 0–9 years and 9 (11.8%) in patients older than 10 years. Four cases resulted in death and eight in cardiopulmonary arrest, all involving serious underlying medical conditions and occurring during prolonged and highly invasive procedures. When categorized by age, six cases (75.0%) involved children aged 0–9 years and 2 (25.0%) involved patients older than 10 years. The most common underlying disease categories were cardiac disease ( n = 7) and the most frequent procedures were cardiac catheterization ( n = 5). The number of physicians exclusively assigned to anesthesia induction and monitoring using capnometers was not reported. Conclusions: This nationwide registry analysis characterizes severe pediatric intravenous anesthesia–related adverse events in Japan and highlights the importance of risk stratification and specialist involvement in high‐risk cases.
- Open Access
- 12 December 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (3) , 492-503
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
- 12 December 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 24 (3) , 492-503
Open AccessFecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
Fecal surrogate markers strongly correlate with endoscopic findings in pediatric onset inflammatory bowel disease: a retrospective study in Japan
- 30 December 2024
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e15855
Immaturity of gut functions and induction of tolerance during early infancy
Tolerance to foreign molecules is primarily induced through three pathways: anergy, active suppression, and clonal deletion. The immaturity of gut functions, including digestion and barrier protection against foreign molecules during early infancy, is closely linked to the induction of tolerance. A significant number of undigested peptides can pass through leaky gut walls during this period, making it an opportune time to introduce active suppression and clonal deletion in the intestine. Increased production and expression of TGF‐β and CXCL13 with lymphoid hyperplasia in early infancy can be a convenient way to introduce tolerance and immunoglobulin A (IgA) synthesis against food and other antigens to protect hosts from allergic diseases. In this article we will discuss the immaturity of gut functions and mucosal immunity in infancy and its relationship to the introduction of tolerance.
- 30 December 2024
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e15855
Immaturity of gut functions and induction of tolerance during early infancy
Tolerance to foreign molecules is primarily induced through three pathways: anergy, active suppression, and clonal deletion. The immaturity of gut functions, including digestion and barrier protection against foreign molecules during early infancy, is closely linked to the induction of tolerance. A significant number of undigested peptides can pass through leaky gut walls during this period, making it an opportune time to introduce active suppression and clonal deletion in the intestine. Increased production and expression of TGF‐β and CXCL13 with lymphoid hyperplasia in early infancy can be a convenient way to introduce tolerance and immunoglobulin A (IgA) synthesis against food and other antigens to protect hosts from allergic diseases. In this article we will discuss the immaturity of gut functions and mucosal immunity in infancy and its relationship to the introduction of tolerance.
- Open Access
- 19 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Staphylococcus aureus δ-toxin present on skin promotes the development of food allergy in a murine model
Background: Patients with food allergy often suffer from atopic dermatitis, in which Staphylococcus aureus colonization is frequently observed. Staphylococcus aureus δ-toxin activates mast cells and promotes T helper 2 type skin inflammation in the tape-stripped murine skin. However, the physiological effects of δ-toxin present on the steady-state skin remain unknown. We aimed to investigate whether δ-toxin present on the steady-state skin impacts the development of food allergy.Material and methods: The non-tape-stripped skins of wild-type, KitW-sh/W-sh, or ST2-deficient mice were treated with ovalbumin (OVA) with or without δ-toxin before intragastric administration of OVA. The frequency of diarrhea, numbers of jejunum or skin mast cells, and serum levels of OVA-specific IgE were measured. Conventional dendritic cell 2 (cDC2) in skin and lymph nodes (LN) were analyzed. The cytokine levels in the skin tissues or culture supernatants of δ-toxin-stimulated murine keratinocytes were measured. Anti-IL-1α antibody-pretreated mice were analyzed.Results: Stimulation with δ-toxin induced the release of IL-1α, but not IL-33, in murine keratinocytes. Epicutaneous treatment with OVA and δ-toxin induced the local production of IL-1α. This treatment induced the translocation of OVA-loaded cDC2 from skin to draining LN and OVA-specific IgE production, independently of mast cells and ST2. This resulted in OVA-administered food allergic responses. In these models, pretreatment with anti-IL-1α antibody inhibited the cDC2 activation and OVA-specific IgE production, thereby dampening food allergic responses.Conclusion: Even without tape stripping, δ-toxin present on skin enhances epicutaneous sensitization to food allergen in an IL-1α-dependent manner, thereby promoting the development of food allergy.
- 19 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Open AccessStaphylococcus aureus δ-toxin present on skin promotes the development of food allergy in a murine model
Background: Patients with food allergy often suffer from atopic dermatitis, in which Staphylococcus aureus colonization is frequently observed. Staphylococcus aureus δ-toxin activates mast cells and promotes T helper 2 type skin inflammation in the tape-stripped murine skin. However, the physiological effects of δ-toxin present on the steady-state skin remain unknown. We aimed to investigate whether δ-toxin present on the steady-state skin impacts the development of food allergy.Material and methods: The non-tape-stripped skins of wild-type, KitW-sh/W-sh, or ST2-deficient mice were treated with ovalbumin (OVA) with or without δ-toxin before intragastric administration of OVA. The frequency of diarrhea, numbers of jejunum or skin mast cells, and serum levels of OVA-specific IgE were measured. Conventional dendritic cell 2 (cDC2) in skin and lymph nodes (LN) were analyzed. The cytokine levels in the skin tissues or culture supernatants of δ-toxin-stimulated murine keratinocytes were measured. Anti-IL-1α antibody-pretreated mice were analyzed.Results: Stimulation with δ-toxin induced the release of IL-1α, but not IL-33, in murine keratinocytes. Epicutaneous treatment with OVA and δ-toxin induced the local production of IL-1α. This treatment induced the translocation of OVA-loaded cDC2 from skin to draining LN and OVA-specific IgE production, independently of mast cells and ST2. This resulted in OVA-administered food allergic responses. In these models, pretreatment with anti-IL-1α antibody inhibited the cDC2 activation and OVA-specific IgE production, thereby dampening food allergic responses.Conclusion: Even without tape stripping, δ-toxin present on skin enhances epicutaneous sensitization to food allergen in an IL-1α-dependent manner, thereby promoting the development of food allergy.
- Open Access
- 1 January 2022
- Published by The Jutendo Medical Journal in Juntendo Medical Journal
- Vol. 68 (3) , 271-281
Evaluating Small Intestinal Motility in a Rat Model of Adolescent Irritable Bowel Syndrome
Objectives The correlation between altered small intestinal motility and irritable bowel syndrome is not well evaluated. This study aimed to assess the small intestinal and colonic transits in an adolescent irritable bowel syndrome rat model with restraint stress and determine the role of small intestinal motility in the irritable bowel syndrome pathophysiology.Materials Restraint stress was utilized to prepare adolescent irritable bowel syndrome rat models that were evaluated for clinical signs, including stool frequency and diarrhea. The small intestinal motility and transit rate were also evaluated.Methods The amounts of mRNA encoding corticotropin-releasing hormone, mast cell, and serotonin (5-Hydroxytryptamine) receptor 3a were quantified using real-time polymerase chain reaction; the 5-Hydroxytryptamine expression was evaluated using immunostaining.Results Restraint stress significantly increased the number of fecal pellet outputs, stool water content, and small intestinal motility in the adolescent irritable bowel syndrome rat models. There was no difference in real-time polymerase chain reaction results; however, immunostaining analysis revealed that 5-Hydroxytryptamine expression in the small intestine was significantly increased in the adolescent irritable bowel syndrome rat models.Conclusions In the rat model of adolescent irritable bowel syndrome with restraint stress, we observed an increase in small intestinal and colonic motility. In the small intestine, enhanced 5-Hydroxytryptamine secretion in the distal portion may be involved in increasing the small intestinal motility. Although the present study focused on 5-Hydroxytryptamine, further investigation of other factors that regulate intestinal peristalsis may lead to the establishment of more effective treatment methods for adolescent irritable bowel syndrome.
- 1 January 2022
- Published by The Jutendo Medical Journal in Juntendo Medical Journal
- Vol. 68 (3) , 271-281
Open AccessEvaluating Small Intestinal Motility in a Rat Model of Adolescent Irritable Bowel Syndrome
Objectives The correlation between altered small intestinal motility and irritable bowel syndrome is not well evaluated. This study aimed to assess the small intestinal and colonic transits in an adolescent irritable bowel syndrome rat model with restraint stress and determine the role of small intestinal motility in the irritable bowel syndrome pathophysiology.Materials Restraint stress was utilized to prepare adolescent irritable bowel syndrome rat models that were evaluated for clinical signs, including stool frequency and diarrhea. The small intestinal motility and transit rate were also evaluated.Methods The amounts of mRNA encoding corticotropin-releasing hormone, mast cell, and serotonin (5-Hydroxytryptamine) receptor 3a were quantified using real-time polymerase chain reaction; the 5-Hydroxytryptamine expression was evaluated using immunostaining.Results Restraint stress significantly increased the number of fecal pellet outputs, stool water content, and small intestinal motility in the adolescent irritable bowel syndrome rat models. There was no difference in real-time polymerase chain reaction results; however, immunostaining analysis revealed that 5-Hydroxytryptamine expression in the small intestine was significantly increased in the adolescent irritable bowel syndrome rat models.Conclusions In the rat model of adolescent irritable bowel syndrome with restraint stress, we observed an increase in small intestinal and colonic motility. In the small intestine, enhanced 5-Hydroxytryptamine secretion in the distal portion may be involved in increasing the small intestinal motility. Although the present study focused on 5-Hydroxytryptamine, further investigation of other factors that regulate intestinal peristalsis may lead to the establishment of more effective treatment methods for adolescent irritable bowel syndrome.
- 18 October 2020
- Published by Wiley in Helicobacter
- Vol. 26 (1) , e12764
Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years
Background: Helicobacter pylori (H. pylori) infection causes chronic gastritis, duodenal and to a lesser extent, gastric ulcers, and gastric cancer. Most H. pylori infections are acquired in childhood, and effective treatment of childhood infection is very important. Esophagogastroduodenoscopy (EGD) is useful for endoscopic diagnosis, mucosal tissue biopsy, and culture examination for H. pylori in children and adults. In this paper, we report results of susceptibility tests and eradication rates in H. pylori‐positive children who underwent EGD over a 12‐year period.Materials and Methods: The subjects were H. pylori‐positive pediatric patients who had gastrointestinal symptoms and underwent EGD in the Department of Pediatrics, Juntendo University Hospital (January 2007–December 2018). Patients underwent serum IgG antibody tests, fecal antigen tests, or urea breath tests, and subsequently, culture tests by gastric mucosal biopsy during EGD. H. pylori positivity was defined as a positive result on both tests. Patients received triple therapy for 14 days using our regimen, and eradication was assessed at 2, 6, and 12 months after therapy.Results: Forty‐five patients were H. pylori‐positive, and the overall clarithromycin (CAM) resistance rate was 71.1 % (32/45). The CAM resistance rate for the 2013–2018 period was significantly higher than the 2007–2012 period (52.6% vs. 84.6%, P < 0.05). According to the results of the antimicrobial susceptibility test, we prescribed effective antibiotics, and this resulted in a primary eradication rate of 97.7%.Conclusions: We suggest that antimicrobial susceptibility testing can significantly improve rates of primary eradication of H. pylori infection.
- 18 October 2020
- Published by Wiley in Helicobacter
- Vol. 26 (1) , e12764
Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single‐center study over 12 years
Background: Helicobacter pylori (H. pylori) infection causes chronic gastritis, duodenal and to a lesser extent, gastric ulcers, and gastric cancer. Most H. pylori infections are acquired in childhood, and effective treatment of childhood infection is very important. Esophagogastroduodenoscopy (EGD) is useful for endoscopic diagnosis, mucosal tissue biopsy, and culture examination for H. pylori in children and adults. In this paper, we report results of susceptibility tests and eradication rates in H. pylori‐positive children who underwent EGD over a 12‐year period.Materials and Methods: The subjects were H. pylori‐positive pediatric patients who had gastrointestinal symptoms and underwent EGD in the Department of Pediatrics, Juntendo University Hospital (January 2007–December 2018). Patients underwent serum IgG antibody tests, fecal antigen tests, or urea breath tests, and subsequently, culture tests by gastric mucosal biopsy during EGD. H. pylori positivity was defined as a positive result on both tests. Patients received triple therapy for 14 days using our regimen, and eradication was assessed at 2, 6, and 12 months after therapy.Results: Forty‐five patients were H. pylori‐positive, and the overall clarithromycin (CAM) resistance rate was 71.1 % (32/45). The CAM resistance rate for the 2013–2018 period was significantly higher than the 2007–2012 period (52.6% vs. 84.6%, P < 0.05). According to the results of the antimicrobial susceptibility test, we prescribed effective antibiotics, and this resulted in a primary eradication rate of 97.7%.Conclusions: We suggest that antimicrobial susceptibility testing can significantly improve rates of primary eradication of H. pylori infection.
- Open Access
- 31 October 2019
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (4) , 476-485
Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
Background/Aims: Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis. Methods: We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients' characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of a >= 20 points compared with baseline. Results: Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11-15] years). 'thirty-nine patients were steroid-dependent and 26 were steroid-refractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05-0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P<0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy. Conclusions: Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.
- 31 October 2019
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 17 (4) , 476-485
Open AccessTacrolimus for ulcerative colitis in children: a multicenter survey in Japan
Background/Aims: Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis. Methods: We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients' characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of a >= 20 points compared with baseline. Results: Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11-15] years). 'thirty-nine patients were steroid-dependent and 26 were steroid-refractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05-0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P<0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy. Conclusions: Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.
- 31 July 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (1) , 114-119
Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan
Background and Aim Childhood‐onset inflammatory bowel disease (IBD) is characterized by extensive intestinal involvement and rapid early progression. Infliximab (IFX), cyclosporin (CYA), and tacrolimus (FK506) are increasingly used to treat pediatric IBD; however, their long‐term effects and adverse events have not been properly investigated in pediatric patients. The aim of this study was to characterize the effects of these biologics and immunomodulators on pediatric IBD patients in Japan. Additionally, we assessed IFX use in pediatric patients with Crohn's disease (CD). Methods A national survey of IFX, adalimumab, CYA, and FK506 use in pediatric IBD patients (< 17 years of age) was sent to 683 facilities in Japan from December 2012 to March 2013. Secondary questionnaires were sent to pediatric and adult practitioners with the aim of assessing the effectiveness and safety of IFX for pediatric CD patients. Results The response rate for the primary survey was 61.2% (N = 418). Among 871 pediatric CD patients, 284 (31.5%), 24, 4, and 15 received IFX (31.5%), adalimumab, CYA, and FK506, respectively, from 2000 to 2012. According to the secondary survey, extensive colitis (L3, Paris classification) was diagnosed in 69.4% of pediatric CD patients who received IFX. Regarding the effectiveness of IFX in this population, 54.7% (99/181) of patients were in remission, and 42.0% (76/181) were on maintenance therapy. However, 32.0% (58/181) of patients experienced adverse events, and one patient died of septic shock. Conclusions Infliximab is reasonably safe and effective in pediatric CD patients and should therefore be administered in refractory cases.
- 31 July 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 32 (1) , 114-119
Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan
Background and Aim Childhood‐onset inflammatory bowel disease (IBD) is characterized by extensive intestinal involvement and rapid early progression. Infliximab (IFX), cyclosporin (CYA), and tacrolimus (FK506) are increasingly used to treat pediatric IBD; however, their long‐term effects and adverse events have not been properly investigated in pediatric patients. The aim of this study was to characterize the effects of these biologics and immunomodulators on pediatric IBD patients in Japan. Additionally, we assessed IFX use in pediatric patients with Crohn's disease (CD). Methods A national survey of IFX, adalimumab, CYA, and FK506 use in pediatric IBD patients (< 17 years of age) was sent to 683 facilities in Japan from December 2012 to March 2013. Secondary questionnaires were sent to pediatric and adult practitioners with the aim of assessing the effectiveness and safety of IFX for pediatric CD patients. Results The response rate for the primary survey was 61.2% (N = 418). Among 871 pediatric CD patients, 284 (31.5%), 24, 4, and 15 received IFX (31.5%), adalimumab, CYA, and FK506, respectively, from 2000 to 2012. According to the secondary survey, extensive colitis (L3, Paris classification) was diagnosed in 69.4% of pediatric CD patients who received IFX. Regarding the effectiveness of IFX in this population, 54.7% (99/181) of patients were in remission, and 42.0% (76/181) were on maintenance therapy. However, 32.0% (58/181) of patients experienced adverse events, and one patient died of septic shock. Conclusions Infliximab is reasonably safe and effective in pediatric CD patients and should therefore be administered in refractory cases.